Accelerate Neurodegeneration Trials With Biomarker Strategies

Bob Dagher, MD, Chief Medical Officer, Clinilabs

Dr. Bob Dagher has more than 20 years of leadership across clinical development, medical affairs, and regulatory strategy in neuropsychiatry, neuroimmunology, and rare disease. He has served as chief medical officer at four biotech companies, leading programs from first-in-human through Phase 3 and BLA submission across mood disorders, psychotic disorders, neurodegeneration, ALS, MS, and rare CNS diseases. Trained in psychiatry at Boston University Medical Center, he holds his M.D. from Bordeaux University and St. Joseph University School of Medicine.

As Chief Medical Officer at Clinilabs, Dr. Dagher brings a distinguished record of leading scientifically complex CNS drug development programs from first-in-human studies through Phase 3 and regulatory submission, precisely the full-development continuum that defines Clinilabs’ mission as the industry’s leading neurotherapeutic CRO, helping sponsor partners accelerate their CNS programs with the precision, integrity, and CNS depth that only Clinilabs delivers.

Robin Wolz, PhD, Chief Scientific Officer (CSO) and Chief Medical Officer (CMO), IXICO

As IXICO’s Chief Scientific Officer, Robin leads the company’s scientific strategy and collaborations with biopharma, academia, and consortia. He drives innovation in MRI, PET, and multimodal imaging to support the development of treatments for neurological diseases. With over 15 years of experience in healthcare analytics and imaging technology, and prior roles at Philips in research and product development, Robin has a proven track record of translating scientific advances into clinical impact. He has authored over 100 peer-reviewed publications and is an inventor on multiple patents in medical imaging and AI.

Brian Murphy, PhD, Co-Founder and Chief Scientific Officer, Cumulus Neuroscience Ltd, Cumulus Neuro

Brian is a computational neuroscientist who is an expert in brain-reading technology, using machine learning methods to decode cognitive states from recordings of brain activity (EEG, fMRI, MEG) and other data.

His academic career included positions as assistant professor in Data Science at Queen’s University Belfast, as senior researcher at Carnegie Mellon University’s Department of Machine Learning, the world’s leading lab for applying machine learning to brain activity, and as post-doc at the Centre for Mind/Brain Sciences, University of Trento, Italy, one of Europe’s leading cognitive neuroscience centres. He has a Ph.D. in Cognitive Science from Trinity College Dublin and prior to academia, worked in and co-founded web startups in Germany and China. Brian is a member of the Alzheimer’s Association EEG PIA committee and organised the MLINI series of workshops on machine learning with neuroimaging data at NeurIPS, the world’s leading machine learning conference.

Dr. Bill Byrom, VP, Product Intelligence and Positioning, Principal, eCOA Science, Senior Visiting Professor, Nottingham Trent University, Signant Health

Bill Byrom is a recognized leader in eClinical product strategy and electronic clinical outcome assessments with over 30 years of pharmaceutical industry experience. He combines deep clinical development expertise with technological innovation to advance digital health solutions. Bill specializes in clinical outcome assessments, sensor-based wearables, and technology-derived endpoints. His research explores COA application in oncology tolerability assessment, new COA measures, and frameworks for COA development from sensor-derived data. Bill consults with pharmaceutical companies and regulatory agencies on digital health initiatives. He has authored numerous publications, including two industry textbooks on ePRO, and serves on key industry committees: ISPOR task forces on ePROs and PerfOs, the C-Path Chronic Heart Failure working group, the EU-funded LABDA research program Executive Advisory Board, and the Duke University PARCR Project Advisory Board.